No abstract

No abstract

No abstract

In our series, severe hypertension with high added risk or very high added risk was very common. Treatment--mostly diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers--required at least two antihypertensive drugs to meet the recommended blood pressure target.

Objectives: (i) to assess the prevalence of SAS in men with MS, (ii) to study the relationship between controlled hypertension and SAS in patients with MS, (iii) to assess the reliability of the ESS to diagnose SAS in patients with MS. Abstracts A1Methods: Among 135 men hospitalized for MS, the 125 who had no history of SAS were systematically evaluated by a nocturnal polygraphy was systematically performed in the 125 men without known SAS at the admission. An excessive daytime sleepiness was assessed by the ESS. Results of analyses in patients with controlled HBP (<130/85 mmHg with antihypertensive drug(s), n = 41) were compared with those in patients with normotension (<130/85 mmHg without treatment, n = 32).Results: The prevalence of SAS (apnea-hypopnea index (AHI) ! 15/h) in men with MS was 44% in the whole population, 28.1% in the subgroup of patients with normotension and 61.0% in patients with treated and controlled HBP. A severe SAS (AHI ! 30/h) was respectively present in 6.3% and 34.1% of patients with normotension and controlled HTA (P < 0.01). Compared with Genetically hypertensive rats of the Lyon strain (LH) associate high blood pressure (BP), exaggerated salt-sensitivity, and a metabolic syndrome made of overweight together with increased plasma lipids and insulin/glucose -Terre, 97100 and g Ré seau de soins sur l'HTA en Guadeloupe: Ré seau HTA-GWAD